FDA Loosens Expanded Access Requirements as Gottlieb Testifies on Right-to-Try Bills

Drug Industry Daily
As federal right-to-try legislation gathers steam on Capitol Hill, the FDA rolled out measures to streamline its expanded access process — including loosening institutional review board requirements — and issued new guidance to manufacturers on its use of adverse event data.

To View This Article:


Subscribe To Drug Industry Daily